LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

• DOI: 10.1016/j.annonc.2021.08.2113
• Publication Date: 2021-09-21T22:25:24Z
• Authors: A. Argiris; K. Harrington; M. Tahara; R.L. Ferris; M. Gillison; J. Fayette; A. Daste; P. Koralewski; R. Mesia Nin; N.F. Saba; M. Mak; M.A. Álvarez Avitia; A. Guminski; U. Müller-Richter; N. Kiyota; M. Roberts; T.A. Khan; K. Miller-Moslin; L. Wei; R. Robert Haddad
• Keywords: Expanded access